Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05510713
Other study ID # jv-fv-RRT
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date September 1, 2022
Est. completion date October 1, 2024

Study information

Verified date August 2022
Source Shanghai Zhongshan Hospital
Contact Zhunyong Gu
Phone 8613918677995
Email gu.zhunyong@zs-hospital.sh.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Acute kidney failure (AKI) is one of the most important causes of morbidity and mortality for critical ill patients. The use of blood purification treatment such as renal replacement therapy (CRRT) and plasma exchange has gradually developed into an effective treatment. However, the efficiency of blood purification may be affected by the recirculation of dual-lumen venous catheter for some special patients including patients with vena cava reflux disorder from massive occupations or ascites. For extreme cases like patients with vena cava disconnection or severe obstruction, the traditional blood purification treatment cannot work effectively. Thus, we used the dual-cannula in jugular-femoral venous blood purification therapy in the following two patients and found that it can improve the perfusion of systemic circulation and the prognosis of patients


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 50
Est. completion date October 1, 2024
Est. primary completion date September 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - 1. patients requiring haemodilution therapy for various reasons (acute renal failure, acute liver failure, etc.) - 2. presence of superior vena cava and/or inferior vena cava reflux disorders - 3. age greater than 18 years Exclusion Criteria: - 1. Inability to establish suitable vascular access - 2. Pregnant women - 3. Not agreeing to active life support treatment - 4. Severe active bleeding

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Hemodialysis Catheter
We add a dialysis catheter to the patient, i.e., replace single-cannula in femoral venous with dual-cannula in jugular-femoral venous

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Shanghai Zhongshan Hospital

Outcome

Type Measure Description Time frame Safety issue
Primary vasoactive drugs doses of vasoactive drugs 144 hours after dual-cannula in jugular-femoral venous
Primary ICU mortality Measurement of ICU mortality 28-day ICU mortality
Secondary Cytokine Checking cytokine levels by laboratory 24hous after dual-cannula in jugular-femoral venous
See also
  Status Clinical Trial Phase
Completed NCT04643639 - Assessing the Effects of CytoSorb Hemoperfusion on the Development on Immunoparalysis Phase 3
Not yet recruiting NCT05595239 - Blood Purification in Septic Children N/A